

Claims

What is claimed is:

1. A fenofibrate composition with an enhanced bioavailability, whereby the required daily dose is lower than 200mg.
- 5 2. The composition of claim 1, wherein the composition has a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or 0.025 M sodium lauryl sulfate.
- 10 3. The composition of claim 1, wherein the fenofibrate is present in an amount of 5 to 50% by weight.
4. The composition of claim 1, wherein the fenofibrate is present in an amount of 20 to 45% by weight.
5. The composition of claim 1 in the form of a tablet.
- 15 6. The composition of claim 1 in the form of a capsule.
7. The composition of claim 1 in the form of granulates.
8. The composition of claim 1 which is once-daily.
9. A fenofibrate composition with an enhanced bioavailability, whereby the required daily dose is lower than 200mg, and wherein the composition has a dissolution of at least 10% in
20 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or 0.025 M sodium lauryl sulfate.
10. The composition of claim 9, wherein the fenofibrate is present in an amount of 5
25 to 50% by weight.
11. The composition of claim 10, wherein the fenofibrate is present in an amount of 20 to 45% by weight.
12. The composition of claim 10 in the form of a tablet.
13. The composition of claim 10 in the form of a capsule.
- 30 14. The composition of claim 10 in the form of granulates.
15. The composition of claim 10 which is once-daily.

16. An orally administrable fenofibrate tablet with an enhanced bioavailability, whereby the required daily dose is lower than 200mg.
17. The tablet of claim 16, wherein the tablet has a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or 0.025 M sodium lauryl sulfate.
18. The tablet of claim 16, wherein the fenofibrate is present in an amount of 5 to 50% by weight.
19. The tablet of claim 16, wherein the fenofibrate is present in an amount of 20 to 45% by weight.
20. The tablet of claim 16 which is once-daily.
21. An orally administrable fenofibrate tablet with an enhanced bioavailability, whereby the required daily dose is lower than 200mg, and wherein the tablet has a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or 0.025 M sodium lauryl sulfate.
22. The tablet of claim 21, wherein the fenofibrate is present in an amount of 5 to 50% by weight.
23. The tablet of claim 21, wherein the fenofibrate is present in an amount of 20 to 45% by weight.
24. The tablet of claim 21 which is once-daily.
25. An orally administrable fenofibrate capsule with an enhanced bioavailability, whereby the required daily dose is lower than 200mg.
26. The capsule of claim 25, wherein the capsule has a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or 0.025 M sodium lauryl sulfate.

27. The capsule of claim 25, wherein the fenofibrate is present in an amount of 5 to 50% by weight.

28. The capsule of claim 25, wherein the fenofibrate is present in an amount of 20 to 45% by weight.

5 29. The capsule of claim 25 which is once-daily.

30. An orally administrable fenofibrate capsule with an enhanced bioavailability, whereby the required daily dose is lower than 200mg, and wherein the capsule has a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia,
10 in a dissolution medium constituted by water with 2% by weight polysorbate 80 or 0.025 M sodium lauryl sulfate.

31. The capsule of claim 30, wherein the fenofibrate is present in an amount of 5 to 50% by weight.

32. The capsule of claim 30, wherein the fenofibrate is present in an amount of 20 to
15 45% by weight.

33. The capsule of claim 30 which is once-daily.

34. The composition according to claim 1, wherein the fenofibrate is in a non-reagglomerated form.

35. The composition according to claim 9, wherein the fenofibrate is in a non-reagglomerated form.
20

36. The tablet according to claim 16, wherein the fenofibrate is in a non-reagglomerated form.

37. The tablet according to claim 21, wherein the fenofibrate is in a non-reagglomerated form.

25 38. The capsule according to claim 25, wherein the fenofibrate is in a non-reagglomerated form.

39. The capsule according to claim 30, wherein the fenofibrate is in a non-reagglomerated form.

30